Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).
Stemler J, Yeghiazaryan L, Stephan C, Mohn KG, Carcas-Sansuan AJ, Rodriguez ER, Moltó J, Mitxeltorena IV, Welte T, Zablockienė B, Akova M, Bethe U, Heringer S, Salmanton-García J, Jeck J, Tischmann L, Zarrouk M, Cüppers A, Biehl LM, Grothe J, Mellinghoff SC, Nacov JA, Neuhann JM, Sprute R, Frías-Iniesta J, Negi R, Gaillard C, Saini G, León AG, Mallon PWG, Lammens C, Hotterbeekx A, Loens K, Malhotra-Kumar S, Goossens H, Kumar-Singh S, König F, Posch M, Koehler P, Cornely OA; EU-COVAT-1 AGED study group on behalf of the VACCELERATE consortium. Stemler J, et al. Among authors: molto j. Int J Infect Dis. 2024 Sep;146:107161. doi: 10.1016/j.ijid.2024.107161. Epub 2024 Jul 9. Int J Infect Dis. 2024. PMID: 38992789 Free article. Clinical Trial.
Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.
Colbers A, Best B, Schalkwijk S, Wang J, Stek A, Hidalgo Tenorio C, Hawkins D, Taylor G, Kreitchmann R, Burchett S, Haberl A, Kabeya K, van Kasteren M, Smith E, Capparelli E, Burger D, Mirochnick M; PANNA Network and the IMPAACT 1026 Study Team. Colbers A, et al. Clin Infect Dis. 2015 Nov 15;61(10):1582-9. doi: 10.1093/cid/civ587. Epub 2015 Jul 22. Clin Infect Dis. 2015. PMID: 26202768 Free PMC article. Clinical Trial.
iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy.
de Jong W, Aerts J, Allard S, Brander C, Buyze J, Florence E, van Gorp E, Vanham G, Leal L, Mothe B, Thielemans K, Plana M, Garcia F, Gruters R; iHIVARNA consortium. de Jong W, et al. Trials. 2019 Jun 17;20(1):361. doi: 10.1186/s13063-019-3409-1. Trials. 2019. PMID: 31208472 Free PMC article. Clinical Trial.
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial.
Moltó J, Valle M, Ferrer E, Domingo P, Curran A, Santos JR, Mateo MG, Di Yacovo MS, Miranda C, Podzamczer D, Clotet B; DRV600 Study Group. Moltó J, et al. J Antimicrob Chemother. 2015 Apr;70(4):1139-45. doi: 10.1093/jac/dku516. Epub 2014 Dec 18. J Antimicrob Chemother. 2015. PMID: 25525195 Clinical Trial.
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
Corominas J, Garriga C, Prenafeta A, Moros A, Cañete M, Barreiro A, González-González L, Madrenas L, Güell I, Clotet B, Izquierdo-Useros N, Raïch-Regué D, Gallemí M, Blanco J, Pradenas E, Trinité B, G Prado J, Pérez-Caballero R, Bernad L, Plana M, Esteban I, Aurrecoechea E, Taleb RA, McSkimming P, Soriano A, Nava J, Anagua JO, Ramos R, Martí Lluch R, Corpes Comes A, Otero Romero S, Martínez-Gómez X, Camacho-Arteaga L, Molto J, Benet S, Bailón L, Arribas JR, Borobia AM, Queiruga Parada J, Navarro-Pérez J, Forner Giner MJ, Lucas RO, Vázquez Jiménez MDM, López Fernández MJ, Alvarez-Mon M, Troncoso D, Arana-Arri E, Meijide S, Imaz-Ayo N, García PM, de la Villa S, Rodríguez Fernández S, Prat T, Torroella È, Ferrer L. Corominas J, et al. Among authors: molto j. Vaccine. 2025 Jan 13;47:126685. doi: 10.1016/j.vaccine.2024.126685. Online ahead of print. Vaccine. 2025. PMID: 39809095
Acrylamide content in popcorn from Spanish market: Risk assessment.
Sebastià A, Fernández-Matarredona C, Castagnini JM, Barba FJ, Berrada H, Moltó JC, Pardo O, Esteve-Turrillas FA, Ferrer E. Sebastià A, et al. Among authors: molto jc. Food Chem Toxicol. 2024 Nov 27;196:115145. doi: 10.1016/j.fct.2024.115145. Online ahead of print. Food Chem Toxicol. 2024. PMID: 39608630
Impact of Dolutegravir plus Lamivudine as First-Line Antiretroviral Treatment on HIV-1 Reservoir and Inflammatory Markers in Peripheral Blood.
Bailón L, Puertas MC, García-Guerrero MC, Moraes-Cardoso I, Aparicio E, Alarcón-Soto Y, Rivero A, Rosen EP, Estes JD, Blanco J, Olvera A, Mothe B, Martinez-Picado J, Moltó J. Bailón L, et al. Among authors: molto j. J Infect Dis. 2024 Oct 28:jiae530. doi: 10.1093/infdis/jiae530. Online ahead of print. J Infect Dis. 2024. PMID: 39465671
Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.
López Fernández MJ, Narejos S, Castro A, Echave-Sustaeta JM, Forner MJ, Arana-Arri E, Molto J, Bernad L, Pérez-Caballero R, Prado JG, Raïch-Regué D, Boreika R, Izquierdo-Useros N, Trinité B, Blanco J, Puig-Barberà J, Natalini Martínez S. López Fernández MJ, et al. Among authors: molto j. Vaccines (Basel). 2024 Jul 25;12(8):840. doi: 10.3390/vaccines12080840. Vaccines (Basel). 2024. PMID: 39203967 Free PMC article.
292 results